Lupin is currently trading at Rs. 736.90, up by 1.70 points or 0.23% from its previous closing of Rs. 735.20 on the BSE.
The scrip opened at Rs. 735.05 and has touched a high and low of Rs. 741.10 and Rs. 728.25 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 697.30 on 19-Jun-2019.
Last one week high and low of the scrip stood at Rs. 745.85 and Rs. 720.55 respectively. The current market cap of the company is Rs. 33356.89 crore.
The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.66% and 14.38% respectively.
Lupin and Boehringer lngelheim have entered into licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.